Healthcare / BiotechnologyBSE
$68.05
+3.05 (+4.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-29.8M · quality 79.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
33.7x
↑EV/EBITDA
82.8x
↑ROE
2.9%
↑Gross Margin
47.1%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-233.8%
FCF / Net income
-18.44x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $84.7M · net income $10.7M · FCF $-198.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $84.7M | $84.7M | $13.4M | $14.6M | — |
| Net Income | $10.7M | $10.7M | $-13.8M | $-12.6M | $-6.6M |
| EBITDA | $14.1M | $14.1M | $-13.0M | $-11.9M | $-5.8M |
| EPS | 0.76 | 0.76 | -2.48 | -2.26 | -0.66 |
| Gross Margin | 47.1% | 47.1% | -33.2% | -5.3% | — |
| Operating Margin | 7.6% | 7.6% | -124.7% | -86.4% | — |
| Net Margin | 12.7% | 12.7% | -103.7% | -86.5% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | -2.60 | -3.27 | 1.00 |
| Current Ratio | 16.87 | 16.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-198.1M | $-198.1M | $-29.8M | $-15.5M | $-13.5M |
| Returns | |||||
| ROE | 2.9% | 2.9% | 67.5% | 189.6% | -110.9% |
| Valuation | |||||
| P/E | 33.69 | 33.69 | — | — | — |
| EV/EBITDA | 82.84 | 82.84 | — | — | — |
| P/B | 3.16 | 3.16 | — | — | 23.30 |
| Growth & Yield | |||||
| Revenue Growth | 534.3% | 534.3% | -8.6% | — | — |
| EPS Growth | 130.6% | 130.6% | -9.7% | -240.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
99.5%
EPS terminal req.
$6.04
Spread vs growth
31.1%
5Y implied EPS CAGR
57.2%
EPS terminal req.
$7.31
Spread vs growth
73.4%
10Y implied EPS CAGR
31.5%
EPS terminal req.
$11.77
Spread vs growth
99.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+44.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.48 → 0.76
Residual
+44.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.